{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:41:20Z","timestamp":1791823280716,"version":"4.3.4"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:p>\n                    M\u00fcllerian adenosarcoma harbors low malignant potential, except in cases with myometrial invasion or sarcomatous overgrowth. The presence of a high-grade stromal component has been proposed as an important pathologic predictor of outcome. We hypothesized that high-grade adenosarcoma has distinct clinical and molecular features, distinct from low-grade adenosarcoma. We analyzed the clinicopathologic features and follow-up of 9 high-grade adenosarcomas and a control group of 9 low-grade adenosarcomas. Comprehensive genomic analysis of the high-grade group was performed targeting exons of 409 oncogenes and tumor suppressor genes. In 1 case, the high-grade and low-grade components were separately sequenced. High-grade and low-grade adenosarcomas were comparable in patient age, myometrial invasion, and stage at presentation. Sarcomatous overgrowth was observed in 2\/9 (22%) low-grade and 8\/9 (89%) high-grade adenosarcomas. Six of 9 (67%) patients with high-grade adenosarcoma developed rapid recurrence; 1 died of her disease. Conversely, no low-grade tumors recurred or metastasized. Sequencing of high-grade adenosarcomas revealed frequent\n                    <jats:italic toggle=\"yes\">TP53<\/jats:italic>\n                    pathway alterations, identified in 7\/9 (78%) cases. p53 expression by immunohistochemistry highly correlated with mutation status. Copy number variations occurred at a mean of 28.8 per tumor; most frequently involved genes included\n                    <jats:italic toggle=\"yes\">CDK4<\/jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">MDM2<\/jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">GNAS<\/jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">SGK1<\/jats:italic>\n                    , and\n                    <jats:italic toggle=\"yes\">DICER1<\/jats:italic>\n                    . High-grade adenosarcoma is an aggressive neoplasm with propensity for short-interval recurrence and metastasis. The proportion of copy number alterations is similar to that reported for adenosarcoma with sarcomatous overgrowth. However, the high frequency of\n                    <jats:italic toggle=\"yes\">TP53<\/jats:italic>\n                    abnormalities is a novel finding, indicating that high-grade adenosarcoma is a distinct subset with driver\n                    <jats:italic toggle=\"yes\">TP53<\/jats:italic>\n                    pathway alterations. p53 immunohistochemistry can be used to confirm the presence of a high-grade component. Given its aggressive potential, the presence of any high-grade component in an adenosarcoma should be reported, even in the absence of sarcomatous overgrowth.\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000000907","type":"journal-article","created":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T21:03:55Z","timestamp":1503435835000},"page":"1513-1522","source":"Crossref","is-referenced-by-count":84,"title":["High-grade M\u00fcllerian Adenosarcoma"],"prefix":"10.1097","volume":"41","author":[{"given":"Anjelica","family":"Hodgson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Amemiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojana","family":"Djordjevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Parra-Herran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0046-8177(90)90198-E","article-title":"Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature","volume":"21","author":"Clement","year":"1990","journal-title":"Hum Pathol"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"286","DOI":"10.5858\/arpa.2014-0523-RS","article-title":"Uterine adenosarcoma","volume":"140","author":"Pinto","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/PAP.0b013e3181cfe732","article-title":"Mullerian adenosarcoma of the female genital tract","volume":"17","author":"McCluggage","year":"2010","journal-title":"Adv Anat Pathol"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2559.2009.03231.x","article-title":"Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients","volume":"54","author":"Abeler","year":"2009","journal-title":"Histopathology"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004347-199204000-00001","article-title":"Adenosarcoma of the uterus: a Gynecologic Oncology Group clinicopathologic study of 31 cases","volume":"11","author":"Kaku","year":"1992","journal-title":"Int J Gynecol Pathol"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.2001.6334","article-title":"Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival","volume":"83","author":"Krivak","year":"2001","journal-title":"Gynecol Oncol"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00000478-198901000-00004","article-title":"M\u00fcllerian adenosarcomas of the uterus with sarcomatous overgrowth. A clinicopathological analysis of 10 cases","volume":"13","author":"Clement","year":"1989","journal-title":"Am J Surg Pathol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/path.4675","article-title":"Uterine adenosarcomas are mesenchymal neoplasms","volume":"238","author":"Piscuoglio","year":"2016","journal-title":"J Pathol"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/path.4442","article-title":"Targeted genomic analysis of M\u00fcllerian adenosarcoma","volume":"235","author":"Howitt","year":"2015","journal-title":"J Pathol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/modpathol.2016.99","article-title":"Genomewide copy number analysis of M\u00fcllerian adenosarcoma identified chromosomal instability in the aggressive subgroup","volume":"29","author":"Lee","year":"2016","journal-title":"Mod Pathol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/sj.bjc.6601894","article-title":"The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website","volume":"91","author":"Bamford","year":"2004","journal-title":"Br J Cancer"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature19057","article-title":"Analysis of protein-coding genetic variation in 60,706 humans","volume":"536","author":"Lek","year":"2016","journal-title":"Nature"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/ng.3037","article-title":"Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma","volume":"46","author":"Lim","year":"2014","journal-title":"Nat Genet"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/his.12712","article-title":"MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast","volume":"67","author":"Piscuoglio","year":"2015","journal-title":"Histopathology"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/PAS.0b013e318181a80d","article-title":"Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma","volume":"33","author":"Gallardo","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygyno.2012.12.036","article-title":"Management of uterine adenosarcomas with and without sarcomatous overgrowth","volume":"129","author":"Tanner","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4103\/0377-4929.101738","article-title":"Clinicopathological spectrum of 19 adenosarcomas of female genital tract, including uncommon clinical associations and immunohistochemical profile, reviewed at a single institution","volume":"55","author":"Rekhi","year":"2012","journal-title":"Indian J Pathol Microbiol"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/PGP.0000000000000287","article-title":"Involvement of chromosome 8 in M\u00fcllerian adenosarcoma","volume":"36","author":"Howitt","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1525-1438.1999.09885.x","article-title":"Adenosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53 and mdm-2 analysis of 11 cases","volume":"9","author":"Blom","year":"1999","journal-title":"Int J Gynecol Cancer"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1006\/gyno.1996.0015","article-title":"The expression of epidermal growth factor receptor, HER-2\/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma","volume":"60","author":"Swisher","year":"1996","journal-title":"Gynecol Oncol"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/modpathol.2011.85","article-title":"Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis","volume":"24","author":"Yemelyanova","year":"2011","journal-title":"Mod Pathol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201711000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T18:32:04Z","timestamp":1695407524000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201711000-00009"}},"subtitle":["Genomic and Clinicopathologic Characterization of a Distinct Neoplasm With Prevalent TP53 Pathway Alterations and Aggressive Behavior"],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000000907","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}